Deregulation of the immune-related transcriptome in Resected human Biliary Tract Cancers
AASLD LiverLearning®, Chiara Braconi, 144133
FGF19 immunostaining as biomarker for trial enrichment testing FGFR4 inhibitors in HCC
AASLD LiverLearning®, Agrin Moeini, 144134
Occurrence of polymorphisms and resistant mutations in the NS3, NS5A and NS5B genes of HCV based on sequences deposited in the European Hepatitis C Virus Database (euHCVdb).
AASLD LiverLearning®, Dimas Kliemann, 144390
Patient Derived Organoids can be derived from biopsies of unresectable cholangiocarcinomas and represent an useful tool for functional tumour characterization
AASLD LiverLearning®, Chiara Braconi, 144135
Baseline Immune Changes following DAA Therapy may Predict Early Viral Clearance
AASLD LiverLearning®, Lisa Barrett, 144391
PD-L1 expression in hepatocellular carcinoma: relationship with clinical and pathological features
AASLD LiverLearning®, Fouad LAFDIL, 144136
Functional Genomic Study Reveals GPR125 as a Novel Regulator for Hepatocyte Lipotoxicity
AASLD LiverLearning®, Robert Plummer, 144392
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry
AASLD LiverLearning®, Su Jong Yu, 144149
Hyperlipidemia and Non-Alcoholic Steatohepatitis are Risk Factors for Hepatocellular Carcinoma Development in the Absence of Cirrhosis
AASLD LiverLearning®, Jennifer Phan, 144150
Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating Sirtuin1expressionin the liver
AASLD LiverLearning®, Chuansheng Wang, 144406
The Expression of Glypican-3 (GPC-3) in Hepatocellular Carcinoma (HCC): An Analysis of 1,643 Cases.
AASLD LiverLearning®, Guanghua Rong, 144151
A Human In Vitro Surrogate System For Studying Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Ryan Feaver, 144407
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment
AASLD LiverLearning®, Cristina Della Corte, 144152
Pharmacological and Molecular inhibition of mTORC1 Activation Reduces Ethanol-Induced ER Stress and Ameliorates Alcoholic Liver Injury in Mice
AASLD LiverLearning®, Hanqing Chen, 144408
Among Adults with Hepatocellular Carcinoma in the United States, Low Income Patients Have Significantly Lower Overall Survival Independent of Tumor Stage and Treatment Received
AASLD LiverLearning®, Melissa Yan, 144165
Biological significance of a disintegrin and metalloproteinase 21 expression in hepatocellular carcinoma
AASLD LiverLearning®, Masaaki Takamura, 144166
Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function
AASLD LiverLearning®, Johnny Amer, 144422
Predictors of Inadequate Ultrasound Quality for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis
AASLD LiverLearning®, Amit Singal, 144167
Simultaneous recruitment of Th17 cells in hepatic tissue and in intra-abdominal visceral fat of NASH patients undergoing bariatric surgery
AASLD LiverLearning®, Monika Rau, 144423
Circulating and intratumoral CD39+FoxP3+ regulatory T cells associate with disease progression in HCC patients
AASLD LiverLearning®, Junliang Fu, 144168
Reduction of Liver Fibrosis by CCR2 antagonist CCX872 in Murine Models of NASH
AASLD LiverLearning®, Zhenhua Miao, 144424
Up-stage Treatment Migration Improved Overall Survival of Selected BCLC B and C Hepatocellular Carcinoma Patients
AASLD LiverLearning®, POH SENG TAN, 144181
Impact of age and race/ethnicity for women with gastrointestinal and hepatobiliary malignancies in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144182
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by affecting GLP-1 and gut microbiota
AASLD LiverLearning®, Jian-Gao Fan, 144438
The prognostic factors after initial RFA for primary hepatocellular carcinoma
AASLD LiverLearning®, Atsuo Takigawa, 144183
The role of cytochrome P450-2E1 in fast food-induced hepatic fibrosis
AASLD LiverLearning®, Mohamed Abdelmegeed, 144439
Birth Cohort Analysis of Incidence, Mortality, Treatment modality and Survival of Hepatocellular Carcinoma in Surveillance, Epidemiology and End Results Registries, 1973-2012
AASLD LiverLearning®, Fanggang Liu, 144184
Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans
AASLD LiverLearning®, Doug Buckley, 144440
Aims of the Workshop
AASLD LiverLearning®, Jorge Bezerra, 154680
radiation induced liver disease after stereotactic body radiation therapy for small hepatocellular carcinoma; risk factor and clinical significance
AASLD LiverLearning®, Young Don Kim, 144197
Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
AASLD LiverLearning®, Tomokazu Kawaoka, 144198
Serum PEDF is an Independent Indicator of Non-Invasive Diagnosis in Non-Alcoholic Steatoheaptitis
AASLD LiverLearning®, Jingmin Zhao, 144454
IL-33, released with hepatectomy, facilitated CCA prognosis
AASLD LiverLearning®, Daisaku Yamada, 144199
NAFLD is Associated with Decreased Oxidation of Orally-Delivered Fatty Acids - a Palmitate Breath Test Study
AASLD LiverLearning®, Gihan Naguib, 144455
The Utility of a Multidisciplinary Liver Tumor Clinic (MDTC) to Treat Patients with Hepatocellular Carcinoma (HCC) at a Large Volume Liver Transplant Center
AASLD LiverLearning®, Ravi Vora, 144200
Impaired Mitophagy Flux Triggers NLRP3 Inflammasome Activation during Lipotoxicity in Primary Rat Hepatocytes
AASLD LiverLearning®, Ning-Ping Zhang, 144456
Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or + daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study)
AASLD LiverLearning®, Victor de Ledinghen, 154959
Human FGF19 but not NGM282, an Engineered Variant of FGF19, Causes Hepatocellular Carcinoma (HCC) In A Diet-Induced Mouse Model of Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Lei Ling, 154960
Overview: The Relationship Between NASH and HCC
AASLD LiverLearning®, Hashem El-Serag, 154705
An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma
AASLD LiverLearning®, Irun Bhan, 154961
Patients’ misconceptions about surveillance for hepatocellular carcinoma: Education is needed.
AASLD LiverLearning®, Faydra Lieveld, 144213
Intrahepatic Cholangiocarcinoma Presenting as LI-RADS 5 'HCC'
AASLD LiverLearning®, Raja Koteswar Dhanekula, 144214
Prognostic values of inflammation and immune-based scores in patients with hepatocellular carcinoma who undergo transarterial chemoembolization
AASLD LiverLearning®, Eun Ju Cho, 144215
Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment
AASLD LiverLearning®, Charles Theuer, 144471
Hepatocellular Carcinoma is Associated with Highest Inpatient Post-Operative Mortality Amongst GI Cancers
AASLD LiverLearning®, George Cholankeril, 144216
In vivo knock-down of bile salt export pump exacerbates the homeostasis of the cholesterol and bile acid metabolism in mouse NAFLD model.
AASLD LiverLearning®, Kazuya Okushin, 144472
Roles of Mac-2 binding protein in the NASH liver fibrosis progression
AASLD LiverLearning®, Yusuke Ebisutani, 144473
A single endoscopic duodenal mucosal resurfacing procedure exerts a sustained improvement in hepatic transaminase levels in a cohort of type 2 diabetes patients
AASLD LiverLearning®, Annieke van Baar, 154974
Discovery of new non-invasive tests algorithms (NITs-Algo) for liver disease in subjects with metabolic factors, using SAF scoring system. A proof of concept demonstrating the impact of disease definitions.
AASLD LiverLearning®, Thierry Poynard, 154975
Improvement in NASH histological activity highly correlates with fibrosis regression.
AASLD LiverLearning®, Vlad Ratziu, 154976
The sustained virologic response achieved by PegIFN/RBV could significantly improve survival of intermediate stage CHC-HCC patients receiving TACE
AASLD LiverLearning®, Wei Teng, 144229
Impact of screening on survival in Hepatocellular Carcinoma patients with Chronic Hepatitis B - A regional U.S. population based study
AASLD LiverLearning®, Rasham Mittal, 144230
Significance of hepatic progenitor cell marker-positive hepatocellular carcinoma and its possible prediction by AFP-L3
AASLD LiverLearning®, Atsunori Tsuchiya, 144231
3-mercaptopyruvate Sulfurtransferase Exacerbates Nonalcoholic Fatty Liver Disease Via the Inhibition of Hydrogen Sulfide Biosynthesis
AASLD LiverLearning®, Mengchun Li, 144487
In vitro model of exercise synergizes with sorafenib through enhanced AMP-activated kinase (AMPK) signaling: A novel approach to augment effectiveness of sorafenib against hepatocellular carcinoma (HCC)
AASLD LiverLearning®, Michelle Zhang, 144232
EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Favorable Anti-inflammatory and Anti-fibrotic Activity In Vitro
AASLD LiverLearning®, Lijuan Jiang, 144488
Nucleotide binding and oligomerization domain like receptors (NLR) inflammasomes in patients with non-alcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, Seong Hee Kang, 144489
Conditional survival estimate in patients with BCLC stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with or without concurrent radiotherapy
AASLD LiverLearning®, In Rae Cho, 144245
Regional differences in admissions and treatment outcomes for patients with hepatocellular carcinoma (HCC) in Thailand: data from the national universal health care
AASLD LiverLearning®, Ml.Taya Kitiyakara, 144246
Outcome of treatment in BCLC-0/A HCC patients in real world practice: impact of treatment response and treatment stage migration in overall survival (OS)
AASLD LiverLearning®, Alessia Gazzola, 144247
Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma
AASLD LiverLearning®, Young Mi Hong, 144248
Serum YKL-40 as a marker of liver fibrosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
AASLD LiverLearning®, Yohei Mano, 144504
The evaluation of endoplasmic reticulum (ER) stress in steatotic hepatocytes under a new 3D perfusion culture system consistent with hepatic portal blood.
AASLD LiverLearning®, Eiji Kakazu, 144505
Xenobiotic metabolism in a mouse model of non-alcoholic fatty liver disease: A case study of the ubiquitous environmental contaminant tetrachloroethylene
AASLD LiverLearning®, Joseph Cichocki, 144506
The efficacy of radiofrequency ablation combined with transcatheter hepatic chemoembolization for patients with BCLC stage B hepatocellular carcinoma: A multicenter retrospective study-propensity score matching
AASLD LiverLearning®, Masashi Hirooka, 144261
PNPLA3 (rs738409 C>G) contributes to low viral load and decreased risk of hepatocellular carcinoma in HCV genotype 1b cirrhotic patients.
AASLD LiverLearning®, Sona Frankova, 144262
A failure of the past is not a determinant of future outcomes: Report of operations performed by liver transplant surgeons in patients with underlying cirrhosis.
AASLD LiverLearning®, Angel Alsina, 144263
Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist
AASLD LiverLearning®, Jennifer Lai, 144264
Body Weight Is a Key Determinant of Alcohol-Induced Shifts in Intestinal Microbial Ecology
AASLD LiverLearning®, Puneet Puri, 144520
B-hydroxybutyrate protects from alcoholic hepatitis via a GPR109a-C/EBPβ dependent pathway
AASLD LiverLearning®, Yonglin Chen, 144521
The Use of HCV Positive Donors in HCV Negative Liver Transplant Recipients
AASLD LiverLearning®, George Cholankeril, 144522
Portal venous flow measured by ultrasound sonography after percutaneous transhepatic portal vein embolization is useful for prediction of hepatic hypertrophy
AASLD LiverLearning®, Shingo Shimada, 144277
Outcomes of Liver Transplant from Elderly Deceased Donors in the United States
AASLD LiverLearning®, Mica Esquenazi, 144278
Liver Transplantation after Share 35: Impact on Pre- and Post-Transplant Costs and Mortality
AASLD LiverLearning®, Clara Nicolas, 144279
Expanding the Utilization of Metabolic Livers for Domino Transplantation: Successful Domino Liver Transplant from a Patient with Propionic Acidemia
AASLD LiverLearning®, Nadia Ovchinsky Nadia, 144293
The Numbers of New Waitlist Registrants and Removals are Outpacing the Number of Liver Transplants: National Trends and Regional Variation from 2003 through 2014
AASLD LiverLearning®, Eric Orman, 144294
Rescue allocation for liver transplantation in a context of organ shortage: what is the fate of otherwise discarded grafts?
AASLD LiverLearning®, Louise Barbier, 144295
Outcomes in Patients with Severe Hepatic Encephalopathy and MELD 30 to 34 Justifies Exception to MELD 35 and Higher
AASLD LiverLearning®, George Cholankeril, 144309
Real World Predictors of Hospital Readmission for Hepatic Encephalopathy after Placement of Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Michael Rowley, 144310
Clinical Characteristics of Balloon-Occluded Retrograde Transvenous Obliteration for Refractory Hepatic Encephalopathy: A Comparison with Occlusion of Portosystemic Shunts for Gastric Varices
AASLD LiverLearning®, Tatsuro Nishimura, 144311
Fecal Microbiota Transplantation from a Rationally Selected Donor is Safe in Patients with Recurrent Hepatic Encephalopathy: Preliminary Data from a Randomized Trial
AASLD LiverLearning®, Jasmohan S. Bajaj, 144325
Good glycemic control contributes to an improvement in hyperammonemia by occlusion of portosystemic shunts in cirrhotic patients with diabetes
AASLD LiverLearning®, Tsuyoshi Ishikawa, 144326
Clinial features of muscle volume loss and reduced handgrip-strength in patients with chronic liver disease
AASLD LiverLearning®, Atsushi Hiraoka, 144327
The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic responce with chronic hepatitis C patients
AASLD LiverLearning®, Ken Nishino, 144341
LDV/SOF combination is associated with 100% SVR in patients with thalassemia major: a preliminary report from an Italian multicenter study
AASLD LiverLearning®, Alessandra Mangia, 144342
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis
AASLD LiverLearning®, Natsuko Kobayashi, 144343
Cell Death Biomarkers in Patients with Alcoholic Liver Disease
AASLD LiverLearning®, Benjamin Woolbright, 144101
Reversal of HCV-specific CD8+ T cell exhaustion after removal of cognate antigen
AASLD LiverLearning®, Pierre Tonnerre, 144357
Prediction And Impact Of Alcohol Abstinence After An Episode Of Alcoholic Hepatitis: A Long-Term Follow-Up Study
AASLD LiverLearning®, Jose Altamirano, 144102
Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naïve patients
AASLD LiverLearning®, Sonya MacParland, 144358
Outcomes following index hospitalization with decompensated alcohol-related cirrhosis versus severe alcoholic hepatitis; a retrospective cohort study.
AASLD LiverLearning®, Dev Katarey, 144103
Rapid changes in circulating lipid/lipoprotein and apolipoprotein profiles during daclatasvir and asunaprevir therapy in chronic hepatitis C virus, genotype 1b-infected patients
AASLD LiverLearning®, Erika Matsunaga, 144359
Absence of Perilipin 2 prevents long-chain ceramide accumulation in the LD fractions of alcohol-fed mice
AASLD LiverLearning®, Amanke Oranu, 144104
Impaired Adipocyte Autophagy Promotes White Adipocyte Browning And Protects Against Alcohol-Induced Liver Injury
AASLD LiverLearning®, Wen-Xing Ding, 144117
Plasma cytokines predict faster viral load decline in patients with chronic hepatitis C treated with direct-acting antivirals - an exploratory analysis
AASLD LiverLearning®, Cheng Wang, 144373
Establishment of a cellular model to study ethanol-induced lipophagy
AASLD LiverLearning®, Xiao-Ming Yin, 144118
Vitamin D antagonizes the expression of genes that are epigenetically regulated by Hepatitis C virus
AASLD LiverLearning®, Ran Tur-Kaspa, 144374
Alcohol Exposure Differentially Regulates Immune Responses of Liver Endothelial Cells and Hepatic Stellate Cells to E. coli Infection
AASLD LiverLearning®, Hugo Rosen, 144119
HCV Cure Decreases Markers of T Cell Exhaustion on Most Peripheral T Cell Subsets in HCV-infected Liver Transplant Patients
AASLD LiverLearning®, Erin Doyle, 144375
HBV replication increases cholesterols via upregulation of SREBP-2/HMGCR and down-regulation of CYP-7α in alcoholic fatty liver mice
AASLD LiverLearning®, Hongwu Wang, 144120